XIAOMI-W
01810
BEKE-W
02423
MEITUAN-W
03690
4
NTES-S
09999
5
BOSS ZHIPIN-W
02076
(FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | |
---|---|---|---|---|---|---|---|---|
Turnover | 24.99%9.03B | 22.93%6.22B | 16.84%1.85B | 15.23%7.22B | --5.06B | --1.59B | 65.67%6.27B | --3.78B |
Operating income | 24.99%9.03B | 22.93%6.22B | 16.84%1.85B | 15.23%7.22B | 5.06B | 1.59B | 65.67%6.27B | 3.78B |
Cost of sales | ---- | -2.24%-3.6B | -8.97%-1.23B | ---- | ---3.52B | ---1.13B | -77.10%-4.47B | ---2.53B |
Operating expenses | -4.11%-5.07B | -2.24%-3.6B | -8.97%-1.23B | -8.87%-4.87B | -3.52B | -1.13B | -77.10%-4.47B | -2.53B |
Gross profit | 68.22%3.96B | 70.21%2.62B | 36.36%621.68M | 31.06%2.35B | 1.54B | 455.91M | 42.74%1.79B | 1.26B |
Selling expenses | 49.39%-348.75K | 39.73%-317K | 34.27%-94K | 4.30%-689.06K | ---526K | ---143K | 7.34%-720K | ---777K |
Administrative expenses | -6.70%-492.29M | -4.66%-651.9M | -11.07%-207.75M | 41.33%-461.37M | ---622.85M | ---187.05M | -100.08%-786.37M | ---393.04M |
Research and development expenses | -22.92%-63.62M | -91.94%-47.89M | -304.71%-16.42M | -87.16%-51.75M | ---24.95M | ---4.06M | -11.29%-27.65M | ---24.85M |
Profit from asset sales | 97.06%-51.57K | ---- | ---- | ---1.75M | ---- | ---- | ---- | ---- |
Revaluation surplus | 63.07%-26.35M | ---- | ---- | ---71.34M | ---- | ---- | ---- | ---- |
-Changes in the fair value of other assets | 63.07%-26.35M | ---- | ---- | ---71.34M | ---- | ---- | ---- | ---- |
Impairment and provision | 45.76%-3.23M | 245.13%1.62M | 289.45%1.47M | -824.84%-5.96M | ---1.12M | ---777K | 67.54%-644K | ---1.98M |
-Other impairment is provision | 45.76%-3.23M | 245.13%1.62M | 289.45%1.47M | -824.84%-5.96M | ---1.12M | ---777K | 67.54%-644K | ---1.98M |
Special items of operating profit | 165.09%81.54M | 2,038.06%82.08M | 101.78%998K | 33.36%30.76M | --3.84M | ---56.12M | 144.15%23.07M | ---52.25M |
Operating profit | 112.65%2.98B | 124.13%2.01B | 92.47%399.89M | 39.76%1.4B | 894.82M | 207.77M | 27.78%1B | 784.61M |
Financing cost | 19.56%-155.36M | -14.99%-164.77M | -21.42%-54.26M | -9.44%-193.14M | ---143.29M | ---44.69M | -1,140.58%-176.49M | ---14.23M |
Share of profits of associates | ---- | 7.08%7.2M | 299.46%7.32M | ---- | --6.72M | ---3.67M | -37,209.09%-4.1M | ---11K |
Adjustment items of earning before tax | -170.06%-4.91M | ---- | ---- | ---1.82M | ---- | ---- | ---- | ---- |
Earning before tax | 133.73%2.82B | 143.72%1.85B | 121.41%352.95M | 46.74%1.21B | 758.25M | 159.41M | 6.70%822.01M | 770.38M |
Tax | -148.63%-833.44M | -197.23%-583.27M | -67.07%-114.68M | -2.16%-335.21M | ---196.23M | ---68.65M | -109.05%-328.13M | ---156.97M |
After-tax profit from continuing operations | 128.00%1.99B | 125.04%1.26B | 162.51%238.26M | 76.37%871.05M | 562.02M | 90.77M | -19.49%493.88M | 613.41M |
Earning after tax | 128.00%1.99B | 125.04%1.26B | 162.51%238.26M | 76.37%871.05M | 562.02M | 90.77M | -19.49%493.88M | 613.41M |
Minority profit | 230.22%221.62M | 322.77%149.51M | 143.28%36.55M | 56.43%67.11M | --35.37M | --15.02M | 36.38%42.9M | --31.46M |
Profit attributable to shareholders | 119.46%1.76B | 111.76%1.12B | 166.32%201.72M | 78.27%803.93M | 526.66M | 75.74M | -22.51%450.98M | 581.95M |
Basic earnings per share | 118.37%1.07 | 112.50%0.68 | 140.00%0.12 | 81.48%0.49 | 0.32 | 0.05 | -22.86%0.27 | 0.35 |
Diluted earnings per share | 118.37%1.07 | 112.50%0.68 | 140.00%0.12 | 81.48%0.49 | 0.32 | 0.05 | -22.86%0.27 | 0.35 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | IAS | IAS | CAS (2007) | IAS | IAS | IAS | IAS |
Audit Opinions | Unqualified Opinion | -- | -- | Unqualified Opinion | -- | -- | Unqualified Opinion | Unqualified Opinion |
Auditor | Ernst & Young | -- | -- | Ernst & Young | -- | -- | Ernst & Young | Ernst & Young |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.